Anti-CD 22 Immunotoxin RFB 4 ( dsFv )-PE 38 ( BL 22 ) for CD 22-Positive Hematologic Malignancies of Childhood : Preclinical Studies and Phase I Clinical Trial
Authors' A Molecular B of the Clini Research, N Cancer Cen Medicine/C Correspon for Cancer 1-3750, 90 Phone: 301